-
公开(公告)号:US11634489B2
公开(公告)日:2023-04-25
申请号:US16835140
申请日:2020-03-30
Applicant: Alector LLC
Inventor: Tina Schwabe , Eric Brown , Philip Kong , Ilaria Tassi , Seung-Joo Lee , Arnon Rosenthal , Robert Pejchal , Nels P. Nielson
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US10849992B1
公开(公告)日:2020-12-01
申请号:US15565063
申请日:2016-04-07
Applicant: ALECTOR LLC
Inventor: Arnon Rosenthal , Tina Schwabe
IPC: G01N33/53 , A61K49/00 , G01N33/533 , G01N33/542 , C07K16/28 , G01N21/64
Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.
-
公开(公告)号:US12186409B2
公开(公告)日:2025-01-07
申请号:US17088237
申请日:2020-11-03
Applicant: Alector LLC
Inventor: Arnon Rosenthal , Tina Schwabe
IPC: G01N33/543 , A61K49/00 , C07K16/28 , G01N21/64 , G01N33/533 , G01N33/542
Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.
-
公开(公告)号:US10676525B2
公开(公告)日:2020-06-09
申请号:US16054680
申请日:2018-08-03
Applicant: ALECTOR LLC
Inventor: Tina Schwabe , Eric Brown , Philip Kong , Ilaria Tassi , Seung-Joo Lee , Arnon Rosenthal , Robert Pejchal , Nels P. Nielson
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20190315858A1
公开(公告)日:2019-10-17
申请号:US16382117
申请日:2019-04-11
Applicant: ALECTOR LLC
Inventor: Kate Monroe , Tina Schwabe , Francesca Avogadri-Connors , Ilaria Tassi , Helen Lam , Arnon Rosenthal
IPC: C07K16/28
Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
-
公开(公告)号:US12215149B2
公开(公告)日:2025-02-04
申请号:US17722624
申请日:2022-04-18
Applicant: Alector LLC
Inventor: Philip Kong , Herve Rhinn , Tina Schwabe , Angie Yee , Arnon Rosenthal
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11472874B2
公开(公告)日:2022-10-18
申请号:US16965676
申请日:2019-01-31
Applicant: Alector LLC
Inventor: Philip Kong , Herve Rhinn , Tina Schwabe , Angie Yee , Ilaria Tassi , Muhammad Abbas Alhawagri , Arnon Rosenthal
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11470827B2
公开(公告)日:2022-10-18
申请号:US16218299
申请日:2018-12-12
Applicant: Alector LLC
Inventor: Ilaria Tassi , Asa Abeliovich , Seung-Joo Lee , Arnon Rosenthal , Tina Schwabe
IPC: A01K67/027 , C07H21/04 , C07K14/705 , A61K49/00
Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.
-
公开(公告)号:US11440957B2
公开(公告)日:2022-09-13
申请号:US16959081
申请日:2018-12-21
Applicant: ALECTOR LLC
Inventor: Arnon Rosenthal , Eric Brown , Tina Schwabe , Angie Yee , Herve Rhinn
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US10308718B2
公开(公告)日:2019-06-04
申请号:US15867609
申请日:2018-01-10
Applicant: ALECTOR LLC
Inventor: Arnon Rosenthal , Tina Schwabe , Michael Kurnellas , Robert Pejchal , Anthony B. Cooper
IPC: C07K16/28 , A61K31/7088
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
-
-
-
-
-
-
-
-
-